Collectively, these results suggest that a FBXW7-MYC-PLK1 signaling circuit underlies the tumorigenesis of MB and validate PLK1 inhibitors as potentially effective therapeutics for MYC-overexpressing cancers. This evidence concerns the gene MYC and cancer.